Dr. Kostas Alevizopoulos joined Ventac Partners in August 2007. He brings more than 17 years of corporate expertise in the development and commercialization of therapeutic, diagnostic, medical device and OTC products. His personal track record includes the management of more than 100 international preclinical and clinical projects (in multiple therapeutic sectors) on behalf of biomedical companies and academic institutions and the development and regulatory approval of roughly 10 health products in various countries and regions globally.
Dr. Alevizopoulos currently serves as the CEO of APIM Therapeutics (a Ventac portfolio company), a cancer drug development company at the CTA/phase I stage. He has also co-founded and/or is involved in several other Ventac portfolio companies. Kostas is actively engaged in search and evaluation of technology opportunities and is currently one of the leading technical experts in Ventac Partners. He also serves as an independent technology expert in various academic, government and corporate projects with a focus in product development across multiple therapeutic sectors and technology licensing. Kostas has a strong network in academia and in several bioclusters in Europe, the US and elsewhere.
Important past positions in his career include: CSO of Gerolymatos International SA (Greece), CEO of Medexis SA (Greece), Head of Preclinical R&D of Biovista, Inc. (United States) and Head of R&D of Apotech Corporation (Switzerland).
Kostas received his biology degree from the University of Athens in Greece and his PhD in Molecular Biology from the University of Lausanne in Switzerland. He has conducted post-doctoral studies at the Swiss Institute of Experimental Cancer Research and the Schering Plough Research Institute (USA) specializing in oncology research. He has published more than 25 peer review publications and he is co-inventor of several patent families. He is also trained in European Patent law (Strasbourg, France).